We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 693

Questionable Policy: New Canadian IP Enforcement Guidelines Miss the Mark on Pharma
  • Borden Ladner Gervais LLP
  • Canada
  • April 5 2016

On March 31, 2016, the Canadian Competition Bureau released a long-awaited substantive update of its Intellectual Property Enforcement Guidelines

Important Developments in Canadian Merger Control and IP Matters
  • Blake Cassels & Graydon LLP
  • Canada
  • April 4 2016

The Competition Bureau (Bureau) has obtained a significant remedy in a merger between non-Canadian companies that was not notifiable in Canada

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade

Protecting Life Science Innovations in Canada - A Year in Review
  • Bereskin & Parr LLP
  • Canada
  • February 12 2016

In this article, we highlight some recent Canadian developments from last year that have particular relevance for the life sciences industry

Rx IP update 2015 mid-year highlights
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 16 2015

The following is a mid-year review of the top IP and regulatory law developments in life sciences in Canada. 1. Still no clarification from Supreme

The top 5 trends in Canadian intellectual property law for 2015
  • Bennett Jones LLP
  • Canada
  • March 3 2015

Last year promised significant changes in Canadian IP law; some of which will be realized in 2015. As the first quarter draws to a close, this year's

Industry news
  • Borden Ladner Gervais LLP
  • Canada
  • December 16 2014

The Patented Medicine Prices Review Board (PMPRB) has released a new report titled "Generic Drugs in Canada, 2013", which compares the prices of

Intellectual property weekly abstracts bulletin week of August 18
  • Borden Ladner Gervais LLP
  • Canada
  • August 20 2014

In this case, Apotex sought to enter the market with its generic version of travoprost. The Court dismissed the proceeding on the basis that Apotex’

Federal court affirms standing for innovative drug manufacturer
  • Gowling WLG
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the

Competition Bureau turns its focus to IP rights in the pharmaceutical industry
  • Baker & McKenzie
  • Canada
  • May 13 2014

Following trends towards increased enforcement activity and a heightened focus on intellectual property in the pharmaceutical industry, the